Brain Tumor Research: Study Shows Potential for Improved Survival Rates Using Stereotactic Radiosurgery

A new study released on treatment for brain metastases may have determined a therapeutic advantage of stereotactic radiosurgery (SRS) over whole-brain radiation therapy (WBRT) in patients diagnosed with the disease.

The observational study presented at the American Society for Radiation Oncology’s 2013 annual meeting compared SRS to WBRT in 413 patients who were diagnosed with non-small cell lung cancer with fewer than four brain metastases. Researchers found that patients treated with SRS had an overall survival of nine months compared to 3.9 months for patients treated with WBRT.

The findings suggest that improved survival rates could be among the benefits that SRS offers to patients diagnosed with the disease. To read more about this study, click here.

Our center uses SRS to treat brain metastases using TrueBeam™ STx technology. For more information about TrueBeam STx treatment for brain tumors or other diseases, visit our conditions treated page here.

This is not intended as medical advice to replace the expertise and judgment of your health care team. It is intended to help you and your family make informed decisions, together with your doctor.